Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KB | Q9UBF8 | 17/20 | 0.69 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.68 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.68 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.53 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL48791 | 0.90 | PI4KB (0.68) | PI4KBPIK3CDPIK3CGPIK3CAPIK3CB | |
| SCHEMBL48423 | 0.90 | PI4KB (0.68) | PI4KBPIK3CDPIK3CGPIK3CAPIK3CB | |
| SCHEMBL48650 | 0.86 | PIK3CD (0.67) | PI4KBPIK3CDPIK3CGPIK3CAPIK3CB | |
| SCHEMBL49055 | 0.85 | PIK3CD (0.66) | PI4KBPIK3CDPIK3CGPIK3CAPIK3CB | |
| SCHEMBL1545892 | 0.85 | PI4KB (0.62) | PI4KBPIK3CDPIK3CGPIK3CA | |
| SCHEMBL48488 | 0.85 | PIK3CD (0.73) | PI4KBPIK3CDPIK3CGPIK3CAPIK3CB | |
| SCHEMBL48498 | 0.84 | PIK3CD (0.72) | PI4KBPIK3CDPIK3CGPIK3CAPIK3CB | |
| SCHEMBL48630 | 0.84 | PIK3CD (0.72) | PI4KBPIK3CDPIK3CGPIK3CAPIK3CB | |
| SCHEMBL49489 | 0.82 | PIK3CD (0.76) | PI4KBPIK3CDPIK3CGPIK3CAPIK3CB | |
| SCHEMBL48486 | 0.81 | PIK3CG (0.69) | PI4KBPIK3CDPIK3CGPIK3CAPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1480962-B1 | 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2011-08-24 | — | — | EP | claimed |
| US-8129541-B2 | 5-phenylthiazole derivatives and use as PI3 kinase inhibitors | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| EP-1480962-B1 | 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2011-08-24 | — | — | EP | disclosed |
| US-20100093690-A1 | 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS | BRUCE IAN | 2010-04-15 | — | — | US | disclosed |
| US-7687637-B2 | 5-phenylthiazole derivatives and use as Pi3 kinase inhibitors | NOVARTIS AG (CH) | 2010-03-30 | — | — | US | disclosed |
| US-20050119320-A1 | 5-phenylthiazole derivatives and use as pi3 kinase inhibitors | NOVARTIS AG (CH) | 2005-06-02 | — | — | US | disclosed |
| EP-1480962-A1 | 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS | Novartis AG (CH) | 2004-12-01 | — | — | EP | disclosed |
| WO-2003072557-A1 | 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2003-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093690-A1 | 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS | PIK3CA, PIK3R5, PIP5K1B | PI4KB 30/4885PIK3CD 4/4885PIK3CG 8/4885 |
| US-20050119320-A1 | 5-phenylthiazole derivatives and use as pi3 kinase inhibitors | PIK3CA, PIK3R5, PIP5K1B | PI4KB 30/4885PIK3CD 4/4885PIK3CG 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.